Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03685162
Other study ID # MOLT-2015-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 27, 2018
Est. completion date February 16, 2023

Study information

Verified date October 2023
Source L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice.


Description:

Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice. The study is divided in two different consecutive parts: - Part 1 [from Informed Consent form (ICF) to last data collected at V4]: patients enrolled are receiving levomethadone maintenance treatment according to clinical practice. - Part 2 (after V4 up to FU): patients are in opioid maintenance treatment with any drug (including levomethadone) according to clinical practice. The maximum duration on-study for a patient will be 405 days [from ICF signature (-30 days from V1) to FU (=360 + 15)]. This study is an open-ended trial. This means that for the enrolment and for the study, no maximum duration has been established. The study, which is a voluntary Post Authorization Safety Study (PASS), will be carried out on approximately 10 centers in Italy. The objectives are to provide further data on the safety profile after long term use and effectiveness of levomethadone, administered according Summary of Product Characteristics (SmPC) and in a real word clinical setting, in opioid-addicted patients undergoing maintenance treatment. Safety will be assessed throughout all the study and safety data will be described and analysed based on Adverse Drug Reactions and corrected QT (QTc) prolongation at 12-lead electrocardiogram (ECG), where available. The effectiveness outcomes are the evaluation of levomethadone maintenance treatment according to investigator's judgment at V4(180 days), based on different questionnaires and assessment.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date February 16, 2023
Est. primary completion date February 16, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female patients, aged = 18 years; - Patients with a diagnosis of opioid addiction according to ICD-10 (ICD 10 F11.2); - Opioid-addicted patients initiating or currently undergoing a maintenance treatment with levomethadone as part of their routine clinical care and according to the approved SmPC; - Patients or legal guardian when applicable must provide their written informed consent to participate in the study. Exclusion Criteria: - Inability to understand study procedures; - Any contraindication stated in the SmPC for the administration of levomethadone according to investigator's judgment; - Patients currently participating in any other clinical trial.

Study Design


Locations

Country Name City State
Italy UOC Dipendenze, ASST Papa Giovanni XXIII Bergamo

Sponsors (1)

Lead Sponsor Collaborator
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety (based on Adverse Drug Reactions) Safety will be assessed throughout all the study and safety data will be described and analysed based on Adverse Drug Reactions. Safety will be described throughout all the study (maximum duration approximately 1 year).
Primary Effectiveness (Addiction Severity) Assessed by Addiction Severity Index (ASI); ASI is a semi-structured interview that consent to assess addiction severity (scale 0-9; 0: no problems, 9: severe problems) of the patient in 7 problem areas. The effectiveness outcomes will be evaluated at V4 (180 days).
Primary Effectiveness (Substance use) The patient will register on a diary the use (days) of heroin, buprenorphine, cocaine. The effectiveness outcomes will be evaluated at V4 (180 days).
Primary Effectiveness (Presence of Catabolites) Assessment (negative/positive) of heroin, methadone, buprenorphine, cocaine in urine. The effectiveness outcomes will be evaluated at V4 (180 days).
Primary Effectiveness (Retention Rate) Retention rate (days) in treatment with levomethadone. The effectiveness outcomes will be evaluated at V4 (180 days).
Primary Effectiveness (Craving) Craving will be assessed using by Visual Analogue Scale (VAS) (0-100mm; 0: no craving, 100: maximum craving) The effectiveness outcomes will be evaluated at V4 (180 days).
Primary Effectiveness (Evaluation of Quality of life) The evaluation of quality of life will be carried out with the Quality of Life Short-Form Health Survey questionnaire (SF-12). This questionnaire takes into account two domains: Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) where the lower the score the more disability and the higher the score the less disability. The effectiveness outcomes will be evaluated at V4 (180 days).
See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT01188421 - Medications Development for Drug Abuse Disorders Phase 1/Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Not yet recruiting NCT05611749 - Duloxetine Impact on Postoperative Pain Control and Outcomes Phase 2
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Recruiting NCT04239235 - Integrating Support Persons Into Recovery N/A
Not yet recruiting NCT03394911 - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction Phase 3
Not yet recruiting NCT02282072 - PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction Phase 0
Not yet recruiting NCT01008072 - Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation. N/A
Completed NCT02696096 - Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence Phase 3
Recruiting NCT05299515 - Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence N/A
Recruiting NCT04309565 - Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support N/A
Completed NCT01590251 - Yoga for Pain and Opioid Dependence Phase 1/Phase 2
Completed NCT01873989 - Testosterone Replacement for Male Opioid Agonist Maintained Patients Phase 1/Phase 2
Active, not recruiting NCT02866266 - ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning N/A
Enrolling by invitation NCT02871232 - Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers N/A